AJANTPHARM2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AJANTPHARM 2019-04-01 2020-03-31 2020-01-20 INR Crores Third quarter Single segment PHARMACEUTICAL 2019-10-01 2019-12-31 Unaudited Standalone 5305500000.00 511700000.00 5817200000.00 1370000000.00 248200000.00 -38000000.00 1070200000.00 8400000.00 225000000.00 1272300000.00 4156100000.00 1661100000.00 -3400000.00 1657700000.00 614500000.00 -40000000.00 574500000.00 0.00 1083200000.00 0.00 0.00 0.00 0.00 1083200000.00 -7400000.00 1075800000.00 1075800000.00 0.00 175400000.00 2 12.41 12.41 0.00 0.00 12.41 12.41 1. The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 5 February 2020. n2. Statutory Auditors have carried out Limited Review of the financial results for the quarter and nine month ended 31st December 2019. n4. During the quarter, nil (nine month 7,500) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by Rs.Nil (nine month Rs. 15,000) and securities premium account by Rs. Nil (nine month Rs. 0.93 crores). n5. The Company has adopted the modified retrospective approach as per Ind AS 116 - Leases to account for its leases, effective from reporting periods beginning 1 April 2019. This has resulted in recognising right of use assets of Rs. 28.14 crores and a corresponding lease liability of Rs. 31.95 crores by adjusting retained earnings by Rs. 2.48 crores (net of deferred tax of Rs. 1.33 crores) as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from rent to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. Due to this change, current quarter profit before tax is higher by Rs. 0.02 crores (nine month is lower by Rs. 0.10 crores). To this extent, performance for the current period ended 31 december 2019 is not comparable with previous period results. n6. The Company operates exclusively in one reportable business segment i.e., Pharmaceuticals . n7. Pursuant to a fire incident on 31 August 2019 at Guwahati plant, certain property, plant and equipment and inventory were damaged. The Company has lodged an initial estimate of loss with the insurance company and the survey is currently in process. The Company has recorded a loss of Rs. 23.27 crores towards impairment of part of property, plant and equipment and inventory arising from the incident. The Company has also recognised a minimum insurance claim receivable of Rs. 21.86 crores in the current nine monthr, for which auditor has given modified opinion. However, Company is confident of receiving the said claim. The aforementioned loss and the income from insurance claim receivable has been presented under exceptional item in the financial result with a net impact of Rs. 1.41 cr. The Company is in process of determining its final claim and will make adjustments to the estimated loss when the assessment is completed. n8. Figures for the previous period's have been regrouped, wherever necessary, to correspond with the figures of the current period. Single segment 2019-04-01 2019-12-31 Unaudited Standalone 16357400000.00 1301000000.00 17658400000.00 3839300000.00 757400000.00 333600000.00 3205600000.00 61700000.00 664000000.00 3952200000.00 12813800000.00 4844600000.00 -14100000.00 4830500000.00 1256000000.00 48300000.00 1304300000.00 0.00 3526200000.00 0.00 0.00 0.00 0.00 3526200000.00 -22300000.00 3503900000.00 3503900000.00 0.00 175400000.00 2 40.41 40.41 0.00 0.00 40.41 40.41 Other Expenses 1272300000.00 Other Expenses 3952200000.00